Get the Stockscreener App
33.29
1.16%
-0.39
After Hours:
32.70
-0.59
-1.77%
Exelixis Inc stock is traded at $33.29, with a volume of 6.43M.
It is down -1.16% in the last 24 hours and down -3.92% over the past month.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$33.68
Open:
$33.3
24h Volume:
6.43M
Relative Volume:
2.95
Market Cap:
$9.51B
Revenue:
$2.08B
Net Income/Loss:
$466.92M
P/E Ratio:
117.51
EPS:
0.2833
Net Cash Flow:
$404.94M
1W Performance:
-4.97%
1M Performance:
-3.92%
6M Performance:
+53.20%
1Y Performance:
+43.37%
1-Day Range:
$33.11
$33.68
1-Week Range:
$33.11
$36.22
52-Week Range:
$19.20
$36.97
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
33.29 | 9.51B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
First Week of August 2025 Options Trading For Exelixis (EXEL) - Nasdaq
Exelixis downgraded to market perform by BMO Capital - MSN
The five-year decline in earnings might be taking its toll on Exelixis (NASDAQ:EXEL) shareholders as stock falls 4.3% over the past week - Simply Wall St
Exelixis (NASDAQ:EXEL) Stock Rating Lowered by BMO Capital Markets - MarketBeat
Franklin Resources Inc. Has $20.85 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam - Yahoo Finance
Exelixis downgraded, price target raised to $40 on CRC drug outlook By Investing.com - Investing.com South Africa
Exelixis downgraded, price target raised to $40 on CRC drug outlook - Investing.com Canada
Zacks Research Has Bullish Estimate for Exelixis Q4 Earnings - MarketBeat
Peering Into Exelixis's Recent Short Interest - Benzinga
Exelixis's SWOT analysis: cancer drug maker's stock faces ip hurdle By Investing.com - Investing.com Canada
Exelixis's SWOT analysis: cancer drug maker's stock faces ip hurdle - Investing.com
Barclays PLC Sells 102,720 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Y Intercept Hong Kong Ltd Lowers Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis downgraded on balanced risk/reward after stock surge By Investing.com - Investing.com South Africa
Exelixis cut to neutral from buy by BofA - MSN
Bank of America Downgrades Exelixis (NASDAQ:EXEL) to Neutral - MarketBeat
Exelixis (EXEL) Cancer Drug Partnership Hits $110M Milestone as ADU-1805 Advances in Clinical Trials - StockTitan
Exelixis downgraded on balanced risk/reward after stock surge - Investing.com
Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies? - Inkl
EXEL: Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies? - StockNews.com
Public Employees Retirement System of Ohio Has $2.95 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Sees Significant Increase in Short Interest - MarketBeat
Retirement Systems of Alabama Grows Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
(EXEL) Investment Report - Stock Traders Daily
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report - Benzinga
Tri Ri Asset Management Corp Buys New Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Kovitz Investment Group Partners LLC Takes Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis's SWOT analysis: cabozantinib drives growth amid ip challenges By Investing.com - Investing.com Canada
Exelixis's SWOT analysis: cabozantinib drives growth amid ip challenges - Investing.com
Unsupported price hikes added $815 million to US drug spending in 2023 - Marketscreener.com
State Street Corp Sells 1,157,988 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why - MSN
Verition Fund Management LLC Invests $1.23 Million in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
2 Biotech Stocks to Buy Hand Over Fist in December - The Motley Fool
17,200 Shares in Exelixis, Inc. (NASDAQ:EXEL) Purchased by Point72 DIFC Ltd - MarketBeat
Cerity Partners LLC Acquires 15,777 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Fmr LLC Has $63.89 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis (LTS:0IJO) Financial Strength : 8 (As of Sep. 2024) - GuruFocus.com
Systematic Financial Management LP Has $30.32 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
NFJ Investment Group LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
18,635 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by Paloma Partners Management Co - MarketBeat
Bank of Montreal Can Buys 35,496 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
BNP Paribas Financial Markets Sells 32,223 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis' (NASDAQ:EXEL) earnings growth rate lags the 29% CAGR delivered to shareholders - Yahoo Finance
Exelixis, Inc. (NASDAQ:EXEL) Stake Lessened by Jacobs Levy Equity Management Inc. - MarketBeat
Erste Asset Management GmbH Purchases New Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Edgestream Partners L.P. - MarketBeat
Which GCs Sold Stock In November? Quest, Exelixis, More - Law360
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):